EN DE
Watch Innovative Eyewear Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Innovative Eyewear Inc. (LUCY) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Innovative Eyewear Inc. stock $0.82, price $0.83, that is 1.1% below the price, quality 34 out of 100. Rating: fairly valued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

IE Innovative Eyewear Inc. logo Thin data Nov 4, 2026

Innovative Eyewear Inc.

LUCY · US
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Revenue last quarter +75% vs. a year ago.
Fair value $0.8160 · Fairly valued
Expensive Growth (revenue 5y +115.7 %/yr in USD)
Mixed vs. peers (4/8)
Insiders sold $29,636 (6M)
Quality 34/100
Negative free cash flow
Narrow moat 9/100
Thin data
⚠ Dilution
Watch Innovative Eyewear Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$117.80 $0.6510 Fair Value $0.8160 Aug 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

51‑month range $0.6510 – $117.80 · fair‑value band $0.5355 – $1.02 · the $0.8250 price screens above the $0.8160 fair value. As of Nov 4, 2026.

Follow Innovative Eyewear in your weekly email

Every Wednesday you see whether Innovative Eyewear is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lucyd, Inc develops and sells smart eyewear in North America.

Show moreShow less

It offers smart eyewear products to enable wearer to listen to music, take and make calls, and use voice assistants and ChatGPT to perform smartphone tasks hands-free, as well as prescription eyeglasses, ready-to-wear sunglasses, safety glasses, and sport glasses under the Lucyd Lyte, Lucyd Armor, Nautica, Eddie Bauer, and Reebok brand names.

The company also provides Lucyd app for unlimited ChatGPT interactions and tech support. It sells its products through e-commerce and a network of retail stores of resellers. The company was formerly known as Innovative Eyewear, Inc. and changed its name to Lucyd, Inc in October 2025.

Lucyd, Inc was founded in 2019 and is headquartered in North Miami, Florida.

Stock analysis

Innovative Eyewear Inc. (LUCY) currently trades at $0.8250, while our model-based Fair Value estimate is $0.8160, so the stock looks roughly fairly valued today (gap 1.1%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $0.5355 (bear) to $1.02 (bull), the price of $0.8250 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Innovative Eyewear Inc. reported revenue of $2.7M in FY2025 versus $691K in FY2021, a compound +40.1%/yr. Reported net income was −$7.6M in FY2025.

Key figures

Market cap $7.4M Micro · P/S ratio 2.20 · EPS (TTM) $−1.29 · Return on equity −84.6% · Return on assets (EBIT) −156% (5-year average) · Operating margin −169% · Revenue (TTM) $3.4M · Revenue growth (YoY) +74.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 53% below its 52-week high and 27% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −1%, LUCY screens cheaper than that median.

Fair Value models

Bear $0.5355 Fair Value $0.8160 Bull $1.02
Price $0.8250 · Downside -1.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.6300 $0.9600 $1.20 52
All 1 models by family
Asset-Based
NCAV (Graham) $0.6300 $0.9600 $1.20 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 98
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 20
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 29
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 8
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 5 officers or directors sold shares worth $29,636 and none bought.

  • SaleDavid Eric CohenChief Technology Officer15,769 shares at $0.9235$14,563Aug 19, 2026
  • SaleHarrison R. GrossChief Executive Officer, Director27,738 shares at $0.8827$24,484Aug 19, 2026
  • SaleJoaquin AbondanoChief Operating Officer9,799 shares at $0.8605$8,432Aug 19, 2026
  • SaleKonrad DabrowskiChief AI & Growth Officer13,627 shares at $0.8717$11,879Aug 19, 2026
  • SaleOswald GayleChief Financial Officer15,533 shares at $0.8650$13,437Aug 19, 2026
  • BuyHarrison R. GrossChief Executive Officer, Director2× since Jan 8, 2026: 3,000 shares, avg. $1.46$4,380Jan 21, 2026
  • BuyOswald GayleChief Financial Officer1,000 shares at $1.67$1,669Jan 13, 2026
  • BuyKonrad DabrowskiChief AI & Growth Officer1,300 shares at $1.58$2,054Jan 8, 2026

Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+62.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+59.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+115.7%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+186.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,145.7% (2020) → −319.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch LUCY, get fair value alerts →

Compare Innovative Eyewear Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 34 · Bottom 25%
Fair Value upside −1.1% · Above median
Profitability
Return on assets −74.9% · Bottom 25%
Operating margin (12 months) −168.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 74.5% · Top 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 0.82× · Cheapest 25%
P/S (12 months) 2.18× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)32 · sector 25
FUTURE (revenue growth)100 · sector 40
PAST (return on equity)0 · sector 30
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.38 $131.27 +45% vs LUCY
EssilorLuxottica Société anonyme EL €193.80 €196.22 +1% vs LUCY
Intuitive Surgical, Inc ISRG $452.80 $353.90 −22% vs LUCY
Medline Inc MDLN $39.64 $28.59 −28% vs LUCY
Alcon Inc ALC CHF 61.30 CHF 34.06 −44% vs LUCY
Becton, Dickinson and Company BDX $211.88 $97.80 −54% vs LUCY
Straumann Holding STMN CHF 104.50 CHF 45.50 −56% vs LUCY
West Pharmaceutical Services, Inc WST $399.81 $139.22 −65% vs LUCY
Sartorius Stedim Biotech S.A DIM €225.80 €54.82 −76% vs LUCY
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs LUCY

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Innovative Eyewear Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Innovative Eyewear Inc. Fair Value". https://www.fairvalue-calculator.com/stock/LUCY

Frequently asked questions

Is Innovative Eyewear Inc. (LUCY) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $0.8160 versus a price of $0.8250, about 1% lower (fairly valued).
What is the fair value of LUCY?
Our model-based fair value for Innovative Eyewear Inc. is $0.8160 (as of Nov 4, 2026), built from audited fundamentals. The current price: $0.8250.
What is the quality score of LUCY?
Innovative Eyewear Inc. has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Innovative Eyewear Inc. (LUCY)?
Our model-based price target is the fair value of $0.8160 (as of Nov 4, 2026) from 1 valuation models. Cautious scenario $0.5355, optimistic scenario $1.02. It is a calculation from audited fundamentals, not an analyst target.
What is the Innovative Eyewear Inc. stock forecast for 2026?
Our models put fair value at $0.8160, about 1% lower versus a price of $0.8250 (fairly valued). Cautious scenario $0.5355, optimistic scenario $1.02. The calculation is refreshed regularly with new filings.
What is the revenue of Innovative Eyewear Inc. (LUCY)?
Innovative Eyewear Inc. reported trailing-twelve-month revenue of about $3.4M (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Innovative Eyewear Inc. (LUCY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Innovative Eyewear Inc. it is $0.8160 per share (as of Nov 4, 2026), against a price of $0.8250. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Innovative Eyewear Inc. stock overvalued or undervalued in 2026?
As of Nov 4, 2026, LUCY trades above its calculated fair value: price $0.8250, fair value $0.8160, a gap of about −1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LUCY?
No. The price is what the market pays today ($0.8250); the fair value is what the company's own numbers justify ($0.8160). For Innovative Eyewear Inc. the two are $0.0090 per share apart. That gap is exactly why we show both numbers side by side.
How much is Innovative Eyewear Inc. worth?
The market values Innovative Eyewear Inc. at about $7.4M (market capitalisation, as of Nov 4, 2026). Per share that is $0.8250; our models calculate a fair value of $0.8160 per share.
What do the bullish and bearish scenarios say about LUCY?
Our models span a range for Innovative Eyewear Inc.: cautious scenario $0.5355, base $0.8160, optimistic $1.02 per share (as of Nov 4, 2026, price $0.8250). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Innovative Eyewear Inc. (LUCY)?
Balance-sheet figures for Innovative Eyewear Inc. (as of Nov 4, 2026): return on equity −84.6%. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is LUCY from its 52-week high?
Innovative Eyewear Inc. trades at $0.8250, about 53% below its 52-week high of $1.77 and 27% above the low of $0.6510 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.8160 is for.
Which stocks are comparable to Innovative Eyewear Inc.?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Innovative Eyewear Inc. stock attractive at the current price?
The data as of Nov 4, 2026: price $0.8250, calculated fair value $0.8160 (−1%), Quality Score 34/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LUCY calculated?
We run Innovative Eyewear Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.8160 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Innovative Eyewear Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Innovative Eyewear Inc. (LUCY)?
The closing price on Nov 6, 2026 was $0.8250. Our model-based fair value is $0.8160, about 1% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Innovative Eyewear Inc. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($0.5355 to $1.02) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Innovative Eyewear Inc.

How large is the market capitalisation of Innovative Eyewear Inc. (LUCY)?
The market capitalisation of Innovative Eyewear Inc. is $7.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Innovative Eyewear Inc. (LUCY)?
The price-to-sales ratio of Innovative Eyewear Inc. is 2.20 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Innovative Eyewear Inc. (LUCY)?
Earnings per share at Innovative Eyewear Inc. are $−1.29. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Innovative Eyewear Inc. (LUCY)?
The return on equity (ROE) of Innovative Eyewear Inc. is −84.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Innovative Eyewear Inc. (LUCY)?
On an EBIT basis the return on assets of Innovative Eyewear Inc. is −156% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Innovative Eyewear Inc. (LUCY)?
The operating margin of Innovative Eyewear Inc. is −169% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Innovative Eyewear Inc. (LUCY)?
Revenue at Innovative Eyewear Inc. is growing +74.5% versus a year earlier (3y avg +59.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Innovative Eyewear Inc. (LUCY) generate?
The free cash flow of Innovative Eyewear Inc. is −$7.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Innovative Eyewear Inc. (LUCY) hold?
Innovative Eyewear Inc. holds more cash than debt, $6.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Innovative Eyewear Inc. in the live analysis

One click puts Innovative Eyewear Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.